JP2022513068A5 - - Google Patents
Info
- Publication number
- JP2022513068A5 JP2022513068A5 JP2021526801A JP2021526801A JP2022513068A5 JP 2022513068 A5 JP2022513068 A5 JP 2022513068A5 JP 2021526801 A JP2021526801 A JP 2021526801A JP 2021526801 A JP2021526801 A JP 2021526801A JP 2022513068 A5 JP2022513068 A5 JP 2022513068A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- loh
- sample
- tmb
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024168315A JP2025000809A (ja) | 2018-11-15 | 2024-09-27 | 免疫療法で治療されたがん患者の応答の予測を改善する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862767979P | 2018-11-15 | 2018-11-15 | |
| US62/767,979 | 2018-11-15 | ||
| PCT/US2019/061710 WO2020102674A1 (en) | 2018-11-15 | 2019-11-15 | Method of improving prediction of response for cancer patients treated with immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024168315A Division JP2025000809A (ja) | 2018-11-15 | 2024-09-27 | 免疫療法で治療されたがん患者の応答の予測を改善する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022513068A JP2022513068A (ja) | 2022-02-07 |
| JP2022513068A5 true JP2022513068A5 (cg-RX-API-DMAC7.html) | 2024-03-11 |
| JP7623281B2 JP7623281B2 (ja) | 2025-01-28 |
Family
ID=70727341
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021526801A Active JP7623281B2 (ja) | 2018-11-15 | 2019-11-15 | 免疫療法で治療されたがん患者の応答の予測を改善する方法 |
| JP2024168315A Pending JP2025000809A (ja) | 2018-11-15 | 2024-09-27 | 免疫療法で治療されたがん患者の応答の予測を改善する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024168315A Pending JP2025000809A (ja) | 2018-11-15 | 2024-09-27 | 免疫療法で治療されたがん患者の応答の予測を改善する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US12497661B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3880246A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7623281B2 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019379167B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3120200A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020102674A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116134155A (zh) * | 2020-08-26 | 2023-05-16 | 瑞泽恩制药公司 | 通过施用pd-1抑制剂治疗癌症的方法 |
| CN111979323A (zh) * | 2020-08-28 | 2020-11-24 | 深圳裕策生物科技有限公司 | 用于预测肿瘤免疫治疗效果的生物标志物检测方法及系统 |
| CN112029861B (zh) * | 2020-09-07 | 2021-09-21 | 臻悦生物科技江苏有限公司 | 基于捕获测序技术的肿瘤突变负荷检测装置及方法 |
| JP2024516230A (ja) * | 2021-04-30 | 2024-04-12 | ジェネンテック, インコーポレイテッド | がんのための治療及び診断方法並びに組成物 |
| WO2023196390A1 (en) * | 2022-04-06 | 2023-10-12 | Foundation Medicine, Inc. | Aneuploidy biomarkers associated with response to anti-cancer therapies |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69933661T3 (de) * | 1998-04-15 | 2012-01-26 | Merck Serono Biodevelopment | Genomische sequenz des 5-lipoxygenase-aktivierenden proteins (flap), polymorphische marker und ihre anwendung in der diagnose von asthma |
| US20030092019A1 (en) * | 2001-01-09 | 2003-05-15 | Millennium Pharmaceuticals, Inc. | Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia |
| EP3327148B1 (en) * | 2010-06-18 | 2021-03-17 | Myriad Genetics, Inc. | Methods of predicting the status of brca1 and brca2 genes in a cancer cell |
| KR20170080697A (ko) * | 2014-11-13 | 2017-07-10 | 더 존스 홉킨스 유니버시티 | 관문 차단 및 미소부수체 불안정성 |
| MA40737A (fr) | 2014-11-21 | 2017-07-04 | Memorial Sloan Kettering Cancer Center | Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1 |
| MX381241B (es) | 2015-04-27 | 2025-03-12 | Cancer Research Tech Ltd | Composición de células t para usarse en el tratamiento del cáncer. |
| US10563266B2 (en) | 2015-07-14 | 2020-02-18 | Personal Genome Diagnostics Inc. | Neoantigen treatment prioritization using multivariate analysis based on: HLA genotype, self-similarity, similarity to known antigens, antigen expression levels and mutant allele frequency |
| GB201516047D0 (en) | 2015-09-10 | 2015-10-28 | Cancer Rec Tech Ltd | Method |
| WO2017151502A1 (en) | 2016-02-29 | 2017-09-08 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
| US11725247B2 (en) * | 2016-02-29 | 2023-08-15 | Foundation Medicine, Inc. | Methods of treating cancer |
| WO2017151524A1 (en) * | 2016-02-29 | 2017-09-08 | Foundation Medicine, Inc. | Methods and systems for evaluating tumor mutational burden |
| US20190247435A1 (en) | 2016-06-29 | 2019-08-15 | The Johns Hopkins University | Neoantigens as targets for immunotherapy |
| US11332530B2 (en) | 2016-09-23 | 2022-05-17 | Memorial Sloan Kettering Cancer Center | Determinants of cancer response to immunotherapy |
| US20190240257A1 (en) | 2016-10-13 | 2019-08-08 | The Johns Hopkins University | Compositions and methods for identifying functional anti-tumor t cell responses |
| US11634777B2 (en) * | 2017-01-13 | 2023-04-25 | The General Hospital Corporation | Resistance to checkpoint blockade therapy |
| EP3601355A1 (en) * | 2017-03-31 | 2020-02-05 | Bristol-Myers Squibb Company | Methods of treating tumor |
| AU2018338441B2 (en) * | 2017-09-25 | 2025-08-14 | Memorial Sloan Kettering Cancer Center | Tumor mutational load and checkpoint immunotherapy |
-
2019
- 2019-11-15 CA CA3120200A patent/CA3120200A1/en active Pending
- 2019-11-15 US US16/685,439 patent/US12497661B2/en active Active
- 2019-11-15 AU AU2019379167A patent/AU2019379167B2/en active Active
- 2019-11-15 EP EP19885138.8A patent/EP3880246A4/en active Pending
- 2019-11-15 JP JP2021526801A patent/JP7623281B2/ja active Active
- 2019-11-15 WO PCT/US2019/061710 patent/WO2020102674A1/en not_active Ceased
-
2024
- 2024-09-27 JP JP2024168315A patent/JP2025000809A/ja active Pending
-
2025
- 2025-11-14 US US19/389,414 patent/US20260071282A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7851982B2 (ja) | 癌のための個別化ワクチン | |
| Iacono et al. | Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study | |
| US20220119796A1 (en) | Methods of capturing cell-free methylated dna and uses of same | |
| Reon et al. | Expression of lncRNAs in low-grade gliomas and glioblastoma multiforme: an in silico analysis | |
| Oyama et al. | Isolation of a novel gene on 8p21. 3–22 whose expression is reduced significantly in human colorectal cancers with liver metastasis | |
| Schweiger et al. | The power of NGS technologies to delineate the genome organization in cancer: from mutations to structural variations and epigenetic alterations | |
| US20140134158A1 (en) | Kras mutations and resistance to anti-egfr treatment | |
| Nome et al. | Common fusion transcripts identified in colorectal cancer cell lines by high-throughput RNA sequencing | |
| JP2023518416A (ja) | 単一細胞の進化を追跡するためのシステム及び方法 | |
| Nome et al. | High frequency of fusion transcripts involving TCF7L2 in colorectal cancer: novel fusion partner and splice variants | |
| Trier Maansson et al. | Cell‐free chromatin immunoprecipitation can determine tumor gene expression in lung cancer patients | |
| Myung et al. | TERT promoter mutations and tumor persistence/recurrence in papillary thyroid cancer | |
| KR101838394B1 (ko) | 뇌실하 영역의 돌연변이 유전자를 이용한 교모세포종 조직 기원의 예측 방법 및 동물 모델 | |
| Noh et al. | Targeted liquid biopsy using irradiation to facilitate the release of cell-free DNA from a spatially aimed tumor tissue | |
| EP2714071B1 (en) | Individualized vaccines for cancer | |
| JP2024529192A (ja) | 組織損傷を検出するための循環無細胞メチル化dnaの使用 | |
| Koh et al. | Detection of a distinctive genomic signature in rhabdoid glioblastoma, a rare disease entity identified by whole exome sequencing and whole transcriptome sequencing | |
| KR20150132206A (ko) | 예측성 바이오마커에 대한 검정법 | |
| CN105506155A (zh) | 检测长链非编码rna loc284454表达量的试剂的应用 | |
| Xu et al. | A pan-cancer analysis of cystatin E/M reveals its dual functional effects and positive regulation of epithelial cell in human tumors | |
| Wang et al. | Oncogenes expand during evolution to withstand somatic amplification | |
| CN110951915A (zh) | 一种慢性乙型肝炎抗病毒治疗应答疗效预测的引物以及试剂盒 | |
| Becker et al. | Deep ion sequencing of amplicon adapter ligated libraries: a novel tool in molecular diagnostics of formalin fixed and paraffin embedded tissues | |
| KR102083956B1 (ko) | 다발성 골수종 환자에서 레날리도마이드 및 덱사메타손의 치료에 대한 예후 예측용 바이오 마커 | |
| Zhou et al. | Genomic and transcriptomic profiling of inflammatory breast cancer reveals distinct molecular characteristics to non-inflammatory breast cancers |